AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03050060
Drug: Nelfinavir Mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01157780
Drug: Lovaza (fish oil)
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
Trial: NCT04568031
Drug: AZD1222
RxNorm normalized name: AZD1222
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects in part 1 will have that route of Administration as Intramuscular, 5 × 1010 vp (nominal, ± 1.5 × 1010 vp) on V2
Trial: NCT00658931
Drug: Drug treatment with Cymbalta
RxNorm normalized name: Cymbalta
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug treatment with Cymbalta
Trial: NCT01565850
Drug: COBI
RxNorm normalized name: Ricobid H
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: COBI 150 mg tablet administered orally once daily
Trial: NCT01027728
Drug: CCX 354-C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;~* Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and~* Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days.
Trial: NCT00727727
Drug: Piribedil
RxNorm normalized name: piribedil
DrugBank: Piribedil (DB12478)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02127775
Drug: Lesinurad 400 mg (manufactured at Site 1)
DrugBank: Lesinurad (DB11560)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02127775
Drug: Lesinurad 400 mg (manufactured at Site 2)
DrugBank: Lesinurad (DB11560)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02283294
Drug: Apixaban
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02283294
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00997529
Drug: nonmyeloablative stem cell transplant
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning includes cytoxan 60mg/kg/d on Days 6 \& 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 \& 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction \& immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression \& do not have signs of GVHD, will receive a DLI
Trial: NCT00421993
Drug: Adapalene/Benzoyl Peroxide
RxNorm normalized name: ADAPALENE/BENZOYL PEROXIDE
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Gel, One application daily in the evening for 12 weeks
Trial: NCT00421993
Drug: Adapalene
RxNorm normalized name: Adapalene
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Gel,One application daily in the evening for 12 weeks
Trial: NCT00421993
Drug: Benzoyl Peroxide
RxNorm normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical Gel, one application daily in the evening for 12 weeks
Trial: NCT00421993
Drug: Topical Gel Vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel Vehicle,one application daily in the evening for 12 weeks
Trial: NCT01994460
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01994460
Drug: Ethambutol
RxNorm normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00280462
Drug: Nifedipine (drug)
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
Trial: NCT00280462
Drug: L-Arginin (drug)
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
Trial: NCT02114684
Drug: moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)\]
Trial: NCT00886457
Drug: Decitabine and Pegylated Interferon-Alfa 2B
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
Trial: NCT00321828
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
Trial: NCT00062010
Drug: 13-cis-retinoic acid
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
Trial: NCT00062010
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
Trial: NCT03416244
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab 240 mg IV fixed dose every two weeks
Trial: NCT03416244
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 1mg/kg IV every six weeks (starting in week 7 after safety assessment)
Trial: NCT00573157
Drug: Atacicept
RxNorm normalized name: Atacicept
DrugBank: Atacicept (DB06399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
Trial: NCT00573157
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
Trial: NCT00432302
Drug: Sagopilone (BAY 86-5302, ZK 219477)
RxNorm normalized name: Sagopilone
DrugBank: Sagopilone (DB12391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First infusion only: 28 mg, containing 14 kBq/7.8 mcg \[14C\]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
Trial: NCT04317183
Drug: chamomile topical oral gel
RxNorm normalized name: Chamomile
DrugBank: Chamomile (DB14357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical constituents of chamomile, such as bisabolol, chamazulene, and the flavonoids apigenin and luteolin, possess anti-inflammatory properties.
Trial: NCT04317183
Drug: Miconazole Topical Gel
RxNorm normalized name: miconazole Topical Gel
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical anti fungal agent
Trial: NCT02944383
Drug: Gemcabene
RxNorm normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcabene tablets administered orally once daily, for 12 weeks.
Trial: NCT00915928
Drug: Perindopril
RxNorm normalized name: Perindopril
DrugBank: Perindopril (DB00790)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2,5 mg daily for 3 months
Trial: NCT01032018
Drug: Sertraline, citalopram, or bupropion
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.~Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam
Trial: NCT00174668
Drug: Insulin Glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal
Trial: NCT00174668
Drug: Insulin Therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NPH (70%) plus regular insulin or insulin aspart (30%)
Trial: NCT00174668
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG
Trial: NCT02453776
Drug: PRECISION dosing Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
Trial: NCT03602781
Drug: iNO
RxNorm normalized name: INO
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: iNO at a dose setting of 75 mcg/kg IBW/hr
Trial: NCT00055614
Drug: topotecan hydrochloride
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00754403
Drug: Pioglitazone and metformin
RxNorm normalized name: Pioglitazone and Metformin Hydrochloride Tablets
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
Trial: NCT00754403
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
Trial: NCT02674321
Drug: SD-809
RxNorm normalized name: Alphanine SD
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01183221
Drug: Syntocinon
RxNorm normalized name: Syntocinon
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose of 24 IU (3 sprays/nostril)
Trial: NCT02883556
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
Trial: NCT01477606
Drug: Midostaurin
RxNorm normalized name: Midostaurin
DrugBank: Midostaurin (DB06595)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.~Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.~Maintenance therapy:~50 mg oral twice daily over one year.
Trial: NCT01477606
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction therapy:~200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)~Consolidation therapy:~Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).~Older patients (\>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2).
Trial: NCT01106664
Drug: ONO-7746
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
Trial: NCT01106664
Drug: ONO-7746
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
Trial: NCT01551641
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
Trial: NCT00131378
Drug: Nutropin AQ growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will give themselves injections of growth hormone every night for 6 months.
Trial: NCT00131378
Drug: Placebo Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will give themselves injections of placebo growth hormone every night for 6 months.
Trial: NCT01477606
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction therapy:~60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)
Trial: NCT00224315
Drug: ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00224315
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01164345
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
Trial: NCT03122067
Drug: oxytocin treatment
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intranasal administration of oxytocin
Trial: NCT00167687
Drug: prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:~Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg
Trial: NCT01956695
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01956695
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01495156
Drug: Lithium treatment in combination with a SGA (Second Generation Antipsychotic)
RxNorm normalized name: Lithium antipsychotics
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.~Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L).
Trial: NCT01430793
Drug: Vitamin D3 600,000 units IM
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
Trial: NCT01430793
Drug: Vitamin D3 600,000 Orally
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain \< 30 ng/ml
Trial: NCT01430793
Drug: Vitamin D3 200,000 units IM
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
Trial: NCT01430793
Drug: Vitamin D3 200,000 Orally
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain \< 30 ng/ml
Trial: NCT04425538
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Either infliximab or infliximab-abda will be used at the discretion of the investigator
Trial: NCT01327885
Drug: Eribulin mesylate 1.4 mg/m^2 intravenous
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an intravenous (IV) bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
Trial: NCT00852969
Drug: Niacin
RxNorm normalized name: Niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg tablets once per day
Trial: NCT02119286
Drug: FF
RxNorm normalized name: MFF
DrugBank: Melphalan flufenamide (DB16627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
Trial: NCT02119286
Drug: VI
RxNorm normalized name: VIG
DrugBank: Human vaccinia virus immune globulin (DB14112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
Trial: NCT02119286
Drug: UMEC
RxNorm normalized name: Umecta
DrugBank: Umeclidinium (DB09076)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
Trial: NCT02402036
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib orally for 21 days every 28 day cycle
Trial: NCT04030065
Drug: Omega 3 fatty acid
RxNorm normalized name: Omega 3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Omega-3 fatty acid oil will be supplemented in intravenous form from preoperative day 1, intra-operatively (anytime during surgery before reperfusion of graft) and from post operative day 1 to day 5 in the study group. The preparation used will be 100 ml injection which contains 10 gm of Omega 3 fatty acids.
Trial: NCT00417404
Drug: Aquasol A
RxNorm normalized name: Aquasol A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM Aquasol A 10,000IU three times weekly
Trial: NCT00417404
Drug: aquasol A
RxNorm normalized name: Aquasol A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000 IU three times weeks, by intramuscular injection
Trial: NCT02349243
Drug: Entacapone
RxNorm normalized name: Entacapone
DrugBank: Entacapone (DB00494)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months